
Opinion|Videos|September 30, 2024
Intro and Overview of Bispecifics in Non-Hodgkin Lymphoma (NHL)
Panelists discuss how bispecific antibodies are transforming the treatment landscape for non-Hodgkin lymphoma by enhancing T cell engagement and targeting malignant B cells effectively.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Provide a brief overview of the use of bispecifics antibiotics (BsAbs) in NHL
- Please give a brief overview of the four bispecific antibodies cuused in NHL
- Mosunetuzumab
- Epicortamab
- Glofitamab
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL
2
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
3
Evaluating the Molecular Landscape in Endometrial Cancer to Optimize Treatment
4
Bria-IMT Shows Extended Survival in Advanced Metastatic Breast Cancer
5
















